111 research outputs found

    Summary of vaccine regimens.

    No full text
    <p># QS-21 & 3D-MPL in o/w emulsion.</p><p>*A: 92UG037 B: 92US715 Bal: Ba-L C:96ZM651 E: 93TH976.</p

    Analysis of antibodies against CD4 inducible (CD4i) epitopes.

    No full text
    <p>A) The presence of co-receptor binding site-directed antibodies was assayed by competition with the mAb, 17b. Competition titer indicates the serum dilution capable of outcompeting 50% of pseudoviral binding to 17b. B) Neutralizing antibody titers against HIV-1 JR-FL isolate without sCD4 treatment. C) Neutralizing antibody titers against HIV-1 JR-FL isolate with sCD4 treatment. D) Effect of V3 peptide treatment on neutralizing activity against sCD4-treated JR-FL.</p

    Ability of vaccinee sera to mediate ADCC activity.

    No full text
    <p>CEMNK<sup>r</sup> target cells were pulsed with gp120 prior to exposure of vaccine serum at a 1∶100 dilution. Target cell lysis indicates the ability of vaccinee serum to mediate cell killing by PBMC from a normal human donor. Dotted line indicates background cell lysis observed with a normal human sera control.</p

    Neutralization titers of <i>N</i>.<i>benthamiana</i>-derived bnAbs and control bnAbs against six Tier 2 HIV isolates (A) and against three SHIV isolates (B) using pseudovirus-based TZM-bl cells.

    No full text
    <p>IC50 values are color coded as indicated. Control bnAb produced in CHO (C) and VRC01 produced in HEK293 (H) cells. CHO1–31 is a pool of two CHO-1 (PG9-like) and CHO-31 (VRC01-like) bnAbs which strongly neutralizes all HIV isolates.</p

    Specificity of vaccine-induced antibody responses as determined through mAb competition.

    No full text
    <p>The ability of serially diluted human immune serum to outcompete binding of mAb to a JR-FL & VSV-G pseudotyped virus was measured. Competition titers indicate the serum dilution preventing 50% of pseudoviral binding to the mAb. A) Competition with carbohydrate-specific mAb, 2G12. B) Competition with V3 loop-specific mAb, 447-52D. C) Competition with CD4bs-specific mAb, b12.</p

    Confirmation of neutralizing activities against representative HIV isolates.

    No full text
    <p>Neutralization antibody titers at 50% inhibition for each serum are shown against either SF162 (A) or SS1196.1 (B). Neutralizing activities against SC422661.8 (C) is shown as the fractions of individual sera from each trial either capable of achieving at least 50% inhibition of infection at a 1∶10 serum dilution (shaded portion) or unable to achieve 50% inhibition (open portion). All p values reaching significance (p<0.05) are presented in the figure. All other comparisons did not reach significant based upon Kruskal-Wallis and Dunn'significance tests.</p

    Inhibition of VRC01, 10–1074, b12 and PGT121 neutralizing activity in the TZM-bl assay against HIV RHPA4259.7 and SHIV-BaL-P4 by different macaque anti-idiotypic antibodies.

    No full text
    <p>Concentrations of each of the bnAb that inhibited the target virus at 50–80% was pre-incubated with or without serial dilutions of 7 different monkey plasma samples (color coded) prior to adding virus. Deviations from this “no serum” control line indicates interference from the macaque sample with neutralization of the bnAb.</p
    corecore